scholarly journals BMP type II receptor as a therapeutic target in pulmonary arterial hypertension

2017 ◽  
Vol 74 (16) ◽  
pp. 2979-2995 ◽  
Author(s):  
Mar Orriols ◽  
Maria Catalina Gomez-Puerto ◽  
Peter ten Dijke
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Therapeutic Target ◽  
Type Ii ◽  
Pulmonary Arterial

scholarly journals Erratum to: BMP type II receptor as a therapeutic target in pulmonary arterial hypertension

2017 ◽  
Vol 74 (16) ◽  
pp. 2997-2997 ◽  
Author(s):  
Mar Orriols ◽  
Maria Catalina Gomez-Puerto ◽  
Peter ten Dijke
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Therapeutic Target ◽  
Type Ii ◽  
Pulmonary Arterial

scholarly journals T6 TRAIL is a potential novel therapeutic target in pulmonary arterial hypertension

Thorax ◽  
2011 ◽  
Vol 66 (Suppl 4) ◽  
pp. A3-A3
Author(s):  
A. G. Hameed ◽  
N. D. Arnold ◽  
J. Pickworth ◽  
J. C. Chamberlain ◽  
C. M. H. Newman ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Therapeutic Target ◽  
Pulmonary Arterial ◽  
Novel Therapeutic

scholarly journals Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension

Circulation ◽  
2020 ◽  
Vol 142 (15) ◽  
pp. 1464-1484 ◽  
Author(s):  
Junichi Omura ◽  
Karima Habbout ◽  
Tsukasa Shimauchi ◽  
Wen-Hui Wu ◽  
Sandra Breuils-Bonnet ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Pulmonary Artery ◽  
Arterial Hypertension ◽  
Therapeutic Target ◽  
Noncoding Rna ◽  
Pulmonary Artery Banding ◽  
Pulmonary Arterial ◽  
Rv Function

Background: Right ventricular (RV) function is the major determinant for both functional capacity and survival in patients with pulmonary arterial hypertension (PAH). Despite the recognized clinical importance of preserving RV function, the subcellular mechanisms that govern the transition from a compensated to a decompensated state remain poorly understood and as a consequence there are no clinically established treatments for RV failure and a paucity of clinically useful biomarkers. Accumulating evidence indicates that long noncoding RNAs are powerful regulators of cardiac development and disease. Nonetheless, their implication in adverse RV remodeling in PAH is unknown. Methods: Expression of the long noncoding RNA H19 was assessed by quantitative PCR in plasma and RV from patients categorized as control RV, compensated RV or decompensated RV based on clinical history and cardiac index. The impact of H19 suppression using GapmeR was explored in 2 rat models mimicking RV failure, namely the monocrotaline and pulmonary artery banding. Echocardiographic, hemodynamic, histological, and biochemical analyses were conducted. In vitro gain- and loss-of-function experiments were performed in rat cardiomyocytes. Results: We demonstrated that H19 is upregulated in decompensated RV from PAH patients and correlates with RV hypertrophy and fibrosis. Similar findings were observed in monocrotaline and pulmonary artery banding rats. We found that silencing H19 limits pathological RV hypertrophy, fibrosis and capillary rarefaction, thus preserving RV function in monocrotaline and pulmonary artery banding rats without affecting pulmonary vascular remodeling. This cardioprotective effect was accompanied by E2F transcription factor 1-mediated upregulation of enhancer of zeste homolog 2. In vitro, knockdown of H19 suppressed cardiomyocyte hypertrophy induced by phenylephrine, while its overexpression has the opposite effect. Finally, we demonstrated that circulating H19 levels in plasma discriminate PAH patients from controls, correlate with RV function and predict long-term survival in 2 independent idiopathic PAH cohorts. Moreover, H19 levels delineate subgroups of patients with differentiated prognosis when combined with the NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels or the risk score proposed by both REVEAL (Registry to Evaluate Early and Long-Term PAH Disease Management) and the 2015 European Pulmonary Hypertension Guidelines. Conclusions: Our findings identify H19 as a new therapeutic target to impede the development of maladaptive RV remodeling and a promising biomarker of PAH severity and prognosis.

Beta 3 adrenoceptor: a potential therapeutic target for pulmonary arterial hypertension

2020 ◽  
Author(s):  
Pedro Mendes Ferreira ◽  
Birger Tielemans ◽  
Allard Wagenaar ◽  
Chantal Dessy ◽  
Jean-Luc Balligand ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Therapeutic Target ◽  
Potential Therapeutic Target ◽  
Pulmonary Arterial

Tumour necrosis factor-related apoptosis-inducing ligand is a novel therapeutic target in pulmonary arterial hypertension

The Lancet ◽  
2013 ◽  
Vol 381 ◽  
pp. S47
Author(s):  
Abdul G Hameed ◽  
Nadine D Arnold ◽  
Janet Chamberlain ◽  
Josephine A Pickworth ◽  
Claudia Paiva ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Tumour Necrosis Factor ◽  
Therapeutic Target ◽  
Tumour Necrosis ◽  
Pulmonary Arterial ◽  
Necrosis Factor ◽  
Novel Therapeutic

scholarly journals An unusual case of hemoptysis secondary to Abernethy malformation type II and hepatopulmonary syndrome, pulmonary arterial hypertension

2021 ◽  
Vol 6 (4) ◽  
pp. 237-240
Author(s):  
Ramakrishna Rachakonda ◽  
Shaik Umar Pasha ◽  
Shaik Abdul Waseem ◽  
Nagarjuna Reddy Sunkara ◽  
Seenu Ayyakannu
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Unusual Case ◽  
Hepatopulmonary Syndrome ◽  
Type Ii ◽  
Abernethy Malformation ◽  
History Of ◽  
Chest X Ray ◽  
Pulmonary Arterial ◽  
Cirrhosis Of Liver

A twenty years old male college student came with history of hemoptysis. His chest X-ray showed diffuse infiltrative shadows and he was diagnosed as a case of a case of pulmonary tuberculosis with hemoptysis. On detailed investigations he was found to have Abernethy malformation Type-II with primitive portal vein joining extrahepatic inferior vanacava leading to cirrhosis of liver, porto-pulmonary syndrome, pulmonary arterial hypertension and hemoptysis.

Sign in / Sign up

Export Citation Format

Share Document